Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of 3-[(4-amino-6-bromo-5,8-dihydro-1-hydroxy-8-imino-5-oxo-2-naphtyl)amino]-N,N,N-trimethylanilinium chloride and 3-[(8-amino-dibromo-5-hydroxy-4-imino-1-oxo-1,4-dihydronaphthalenyl)amino]-N,N,N-trimethylbenzenaminium chloride and 3-[(bromo-1,4-dihydroxy-8-imino-5-oxo-5,8-dihydronaphthalenyl)amino]-N,N,N-trimethylbenzenaminium chloride
EC number: 916-466-1 | CAS number: -
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Basic Blue 99 was tested in vitro in an Ames test performed according to OECD guideline 471. A biological relevant mutagenic potential was demonstrated in the absence and presence of metabolic activation. Basic Blue 99 was tested in a mouse lymphoma assay performed according to OECD guideline 476. The substance was considered to be non-mutagenic in the study. Basic Blue 99 was tested in an in vitro micronucleus test performed according to OECD guideline 487. Under the conditions of the study a micronuclei inducing potential was detected for the test item.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
Basic Blue 99 was tested in vivo in a micronucleus assay performed according to OECD guideline 474. The test item did not induce a biologically relevant increase in the number of micronucleated polychromatic erythrocytes in bone marrow cells and is considered to be non-mutagenic. Basic Blue 99 was used in an unscheduled DNA synthesis assay performed according to OECD guideline 486. The test item did not induce DNA damage leading to increased repair synthesis and is considered to be non-mutagenic in the in vivo UDS test system. Considering the negative results obtained in the unscheduled DNA synthesis and mouse lymphoma assays, Basic Blue 99 does not possess a mutagenic potential. The aneugenicity/clastogenicity potential of Basic Blue 99 is cleared by the negative result returned in the in vivo micronucleus assay.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
